A membrane building block that helps run the cell's self-cleaning recycling system, which slows with age. In simple organisms it extended lifespan, but no human study confirms this. The clearest human benefit is modest: an oily appetite-signal form, usually paired with a green-tea compound, helped overweight adults diet better. Longevity claims remain unproven. (Full Review)

Protocol

Standard Regimen

85–180 mg NOPE + 50–120 mg EGCG/day

Best-studied human use is the NOPE-EGCG combination (PhosphoLean) for satiety/metabolic support. No validated human protocol exists for pure PE or ethanolamine for longevity/autophagy.

Timing

~60 min before meals

Pre-meal dosing aligns with the appetite-signaling mechanism. For a hypothetical autophagy use, timing around a fasting window is a logical but unproven choice.

Dosing Pattern

Split before each main meal

Split dosing matches the short-lived nature of the appetite signal and is preferable to a single daily dose for the satiety purpose.

Time to effect

Appetite & Adherence

Days to a few weeks

Effects on appetite and diet adherence emerge over days to a few weeks of consistent pre-meal use.

Body Composition

8 weeks or more

Body-composition changes in trials accrued over 8 weeks or more.

Autophagy / Longevity

No defined time to effect

For autophagy or longevity, there is no measurable human endpoint and therefore no defined time to effect.

Benefits

Medium: Improved diet adherence and modest body-fat reduction (NOPE form)

Low: Enhanced autophagy; lifespan and healthspan extension (model organisms); anti-oxidant and stress resistance

Speculative: Reduced impulsive eating and alcohol-related impulsivity; cardiometabolic and anti-inflammatory support

Contraindications

Active liver disease or history of green-tea-extract liver injury (NOPE-EGCG products)

Pregnancy or breastfeeding

Children

Known phospholipid-handling disorders (without specialist input)

Key Interactions

Warfarin, some chemotherapy agents (e.g., bortezomib) (via EGCG)

Acetaminophen (paracetamol) (via EGCG liver burden)

Other green-tea-extract or high-catechin supplements

Autophagy-promoting supplements (spermidine, resveratrol, ethanolamine)

Appetite-reducing supplements or medications (e.g., GLP-1 receptor agonists)

Fasting and caloric restriction

Risk & Side Effects

Medium: Gastrointestinal discomfort

Low: Disrupted PE/phosphatidylcholine balance and liver strain; confounding from combination products (NOPE-EGCG)

Speculative: Pro-oxidant effect from excess hormesis; unknown effects in disease-relevant pathways

Monitoring

Marker	Target	Why
ALT	< 25 U/L (men), < 20 U/L (women)	Detects liver strain, mainly from EGCG co-ingredient
AST	< 25 U/L	Complements ALT for liver-cell injury
Fasting insulin	2–6 µIU/mL	Tracks the insulin-sensitivity benefit seen in NOPE trials
Fasting glucose	75–90 mg/dL	Monitors metabolic effect and safety
GGT	< 20 U/L (men), < 15 U/L (women)	Sensitive early marker of liver/oxidative stress from catechins
Lipid panel (incl. LDL cholesterol)	LDL context-dependent; triglycerides < 80 mg/dL	Phospholipid handling and cardiometabolic context

Cadence: Baseline, at ~8–12 weeks after starting, then every 6–12 months if continued, with closer attention if an EGCG-containing product is used.

Qualitative Assessment

Appetite and sense of fullness between meals
Adherence to an intended eating pattern
Energy levels and daytime alertness
Digestive comfort (nausea, bloating, stool changes)
Any warning signs of liver stress (dark urine, jaundice, unusual fatigue)

Phosphatidylethanolamine for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment